Targeted therapy can target a variety of tumors, commonly including lung cancer, breast cancer, gastrointestinal tumors, non-Hodgkin’s lymphoma, leukemia, etc. Since targeted therapy is a treatment targeting the clear oncogenic proteins or mutated fragments of genes, genetic testing is required before doing targeted therapy, and only tumor patients who are sensitive to targeted drugs can achieve better therapeutic effects. Clinically, targeted therapy is mainly used for the treatment of the following types of tumors: 1. Lung cancer: for lung cancer patients with EGFR gene mutation, drugs such as erlotinib and gefitinib can be applied for targeted therapy. For lung cancer patients with other gene mutations, crizotinib and other drugs can be applied for targeted therapy; 2. For patients with intestinal cancer, bevacizumab, cetuximab and other drugs can be used for targeted therapy, which is more suitable for patients with advanced intestinal cancer with liver metastases to help improve patients’ quality of life; 4, non-Hodgkin’s lymphoma: for patients with non-Hodgkin’s lymphoma with CD20 mutation, rituximab and other drugs can be used for targeted therapy; 5, leukemia: for acute myeloid leukemia, encystedipine, midostaurin and other drugs can be used for targeted therapy. For acute lymphoblastic leukemia, Imatinib, etolizumab and other drugs can be applied for targeted therapy; 6. Other: liver cancer, malignant pleural mesothelioma and other tumors can be applied for targeted therapy after genetic testing confirms that they are sensitive to targeted drugs.